Chang Chun High and New Technology Industry (Group) (000661) Stock Price, Fundamentals & Analysis

What 000661 does

Chang Chun High and New Technology Industry (Group) (000661) is a stock listed on the Shenzhen Stock Exchange in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines in China, with products including recombinant human growth hormone injection, herpes zoster vaccines, and live attenuated influenza nasal spray. It also develops real estate properties. The company was founded in 1993 and is headquartered in Changchun, China, employing 10,080 people.

Key numbers explained

• 70.85 CNY is the current share price, representing the last traded value in CNY.
• The forward P/E ratio of 6.4 divides the current price by expected future earnings; a lower figure often suggests the market expects lower growth relative to peers.
• Earnings per share, trailing 12 months is -0.87 CNY, meaning the company lost money on a per-share basis over the last twelve months.
• The dividend yield of 0.23% indicates the annual dividend payment as a percentage of the current share price.
• The ex-dividend date of May 25, 2026 is the cutoff date; buying before this date qualifies you for the upcoming dividend payment.
• A beta of 0.31 suggests the stock has historically been less volatile than the overall market.
• Market cap of 28.9B CNY reflects the total market value of all outstanding shares.
• Revenue, trailing 12 months of 11.02 mld. CNY shows the total sales over the last twelve months, while revenue growth, year over year of -18% indicates a decline compared to the prior year.

What to watch

Investors tracking Chang Chun High and New Technology Industry (Group) (000661) may monitor its position among peers such as Hualan Biological Engineering (002007) and Shijiazhuang Yiling Pharmaceutical (002603), which operate in related biopharmaceutical segments. The stock's -45% price change over the last 52 weeks and its 52-week range of 61.09 – 141.77 highlight significant price swings. The debt-to-equity ratio of 9.1% indicates a relatively low level of debt compared to equity. As a Healthcare stock, it is influenced by regulatory approvals, drug pipeline developments, and broader sector trends. It is part of the Shenzhen Stock Exchange stocks universe, which includes a wide range of Chinese-listed companies.